Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration | Zendy

Aurélie Fayet Mello | Zendy; Thierry Buclin | Zendy; Céline Franc | Zendy; Sara Colombo | Zendy; S. Cruchon | Zendy; N. Guignard | Zendy; Jérôme Biollaz | Zendy; Amalio Telenti | Zendy; Laurent A. Décosterd | Zendy; Matthias Cavassini | Zendy

Open Access

Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration

Author(s) -

Aurélie Fayet Mello,

Thierry Buclin,

Céline Franc,

Sara Colombo,

S. Cruchon,

N. Guignard,

Jérôme Biollaz,

Amalio Telenti,

Laurent A. Décosterd,

Matthias Cavassini

Publication year - 2011

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkr151

Subject(s) - raltegravir , darunavir , maraviroc , etravirine , pharmacokinetics , pharmacology , chemistry , integrase inhibitor , ritonavir , chromatography , viral load , medicine , human immunodeficiency virus (hiv) , immunology , antiretroviral therapy

The site of pharmacological activity of raltegravir is intracellular. Our aim was to determine the extent of raltegravir cellular penetration and whether raltegravir total plasma concentration (C(tot)) predicts cellular concentration (C(cell)).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research